NCT04524000 2026-01-12
Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant in Japanese Men and Postmenopausal Women With Advanced Breast Cancer
Novartis
Phase 2 Active not recruiting
Clinical Trials
7 trialsNCT07180160 2025-11-18
ITHRAN
RenJi Hospital
Phase 2 Recruiting
NCT05536128 2025-04-17
Post-CDK
Seoul National University Hospital
Phase 2 Recruiting
NCT04862143 2024-06-20
TELEPIK
Novartis
Phase 2 Terminated
NCT03182634 2019-01-22
plasmaMATCH
Institute of Cancer Research, United Kingdom
Phase 2 Unknown
NCT00454805 2016-08-03
AZD2171 in Addition to Fulvestrant in Patients With Advanced Breast Cancer.
AstraZeneca
Phase 2 Completed
NCT00754325 2016-05-26
Randomized Trial of Fulvestrant With or Without Dasatinib in Men and Postmenopausal Women Who Have Hormone Receptor-positive Advanced Breast Cancer Previously Treated With an Aromatase Inhibitor
Bristol-Myers Squibb
Phase 2 Completed